<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734147</url>
  </required_header>
  <id_info>
    <org_study_id>603204</org_study_id>
    <nct_id>NCT02734147</nct_id>
  </id_info>
  <brief_title>High Dose Intravenous Ascorbic Acid in Severe Sepsis</brief_title>
  <official_title>The Efficacy of Intravenous Ascorbic Acid in Patients With Severe Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christiana Care Health Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Christiana Care Health Services</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite an organized treatment approach outlined in expert-consensus guidelines for sepsis&#xD;
      with fluid resuscitation to treat hypovolemia, antibiotics to target the infectious insult,&#xD;
      and vasopressors for hypotension, mortality rates for sepsis remain high and the incidence&#xD;
      continues to rise, making sepsis the most expensive inpatient disease.&#xD;
&#xD;
        1. Recent research has described the therapeutic benefits associated with ascorbic acid&#xD;
           treatment for sepsis.&#xD;
&#xD;
        2. Researchers objectives are to perform a randomized-controlled clinical trial&#xD;
           investigating the ability of ascorbic acid(vitamin C) administration to decrease organ&#xD;
           dysfunction in severe sepsis. The widespread occurrence of microvascular dysfunction in&#xD;
           sepsis leading to tissue hypoxia, mitochondrial dysfunction, and adenosine triphosphate&#xD;
           (ATP) depletion, gives rise to organ failure.&#xD;
&#xD;
        3. Patients with organ failure and sepsis (severe sepsis) are at a higher risk of death&#xD;
           than patients with organ failure alone. Critically ill patients may have an increased&#xD;
           requirement for ascorbic acid in sepsis and these patients frequently have levels below&#xD;
           normal. Ascorbic acid administration, has been shown to correlate inversely with organ&#xD;
           failure (human literature) and directly with survival (animal studies).&#xD;
&#xD;
      4,5 Intravenous ascorbic acid therapy decreases organ failure by providing a protective&#xD;
      effect on several microvascular functions including improving capillary blood flow,&#xD;
      decreasing microvascular permeability, and improving arteriolar responsiveness to&#xD;
      vasoconstrictors. Defining the utility of novel agents to augment researchers care for severe&#xD;
      sepsis is an important task as investigators continue the institutional focus on sepsis care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial prematurely terminated due to the loss of funding.&#xD;
  </why_stopped>
  <start_date>April 1, 2016</start_date>
  <completion_date type="Actual">November 23, 2017</completion_date>
  <primary_completion_date type="Actual">October 8, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Modified SOFA Score</measure>
    <time_frame>Baseline and 72 hours</time_frame>
    <description>Sequential Organ Failure Assessment (SOFA) Score included the degree of dysfunction of six organ systems (Respiratory, Cardiovascular, Liver, Renal, Coagulation, Neurologic. A modification of the SOFA includes the exclusion of the Liver function. Total score is reported, minimum score = 0 maximum score = 20. Higher scores indicate greater degree of dysfunction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified SOFA Score</measure>
    <time_frame>at 72 Hours</time_frame>
    <description>Sequential Organ Failure Assessment (SOFA) Score included the degree of dysfunction of six organ systems (Respiratory, Cardiovascular, Liver, Renal, Coagulation, Neurologic. A modification of the SOFA includes the exclusion of the Liver function. Total score is reported, minimum score = 0 maximum score = 20. Higher scores indicate greater dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascorbic Acid Concentration at 32 Hours</measure>
    <time_frame>32 Hours</time_frame>
    <description>Ascorbic Acid Concentration Normal Ascorbic Acid Range 0.4-2.0 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Length of Stay</measure>
    <time_frame>Length of ICU stay up to 200 hours</time_frame>
    <description>ICU Length of Stay in Hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>From ICU admission through ICU discharge, up to 2 weeks</time_frame>
    <description>From admission until discharge from ICU in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PIRO Score</measure>
    <time_frame>Baseline and 72 hours</time_frame>
    <description>PIRO consists of 4 assessments, Predisposition (scored 0-9), Infection (scored 0-4), Response (scored 0-6), and Organ Failure (scored 0-14) (PIRO). The total PIRO score is the sum of all subscores and ranges from 0-33 with higher scores indicating worse health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Died</measure>
    <time_frame>From initial hospital admission through discharge, up to 2 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>High dose IV ascorbic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <arm_group_label>High dose IV ascorbic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with:&#xD;
&#xD;
          1. A suspected or confirmed infection with an order for intravenous antibiotics or&#xD;
             antivirals&#xD;
&#xD;
          2. The presence of acute sepsis-induced organ dysfunction&#xD;
&#xD;
        Definition of organ dysfunction:&#xD;
&#xD;
          1. Arterial hypoxemia [PaO2 /FiO2 &lt; 300]&#xD;
&#xD;
          2. Hypotension [systolic blood pressure (SBP) &lt; 90 mmHg or SBP decrease &gt; 40 mmHg]&#xD;
&#xD;
          3. Lactic acidosis [lactate &gt; 2.5 mmol/L]&#xD;
&#xD;
          4. Acute kidney injury [creatinine &gt;2.0 or urine output &lt; 0.5 ml/kg/hr for &gt;2 hours&#xD;
             despite fluid resuscitation]&#xD;
&#xD;
          5. Thrombocytopenia [platelet count &lt; 100,000]&#xD;
&#xD;
          6. Acute coagulopathy [international normalized ratio (INR) &gt; 1.5]&#xD;
&#xD;
          7. Hepatic failure [bilirubin &gt; 2 mg/dL].&#xD;
&#xD;
          8. Predisposition, Infection, Response, and Organ Failure (PIRO) score â‰¥ 10&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 18 years&#xD;
&#xD;
          2. Pregnancy or breastfeeding&#xD;
&#xD;
          3. Requirement for immediate surgery within the treatment protocol timeframe&#xD;
&#xD;
          4. Inability to obtain written informed consent from subject or surrogate&#xD;
&#xD;
          5. Patient to receive comfort measures only&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Arnold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christiana Care Health Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jamie Rosini, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christiana Care Health Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chrisitana Care Health System-Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <results_first_submitted>March 6, 2020</results_first_submitted>
  <results_first_submitted_qc>January 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 16, 2021</results_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT02734147/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Dose IV Ascorbic Acid</title>
          <description>Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.&#xD;
Ascorbic Acid&#xD;
Participant Started: 12 Participant Completed: 9</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.&#xD;
Normal Saline&#xD;
Participant Started: 12 Participant Completed: 11</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose IV Ascorbic Acid</title>
          <description>Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.&#xD;
Ascorbic Acid</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.&#xD;
Normal Saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.6" spread="13.6"/>
                    <measurement group_id="B2" value="70.2" spread="14.4"/>
                    <measurement group_id="B3" value="68.9" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ascorbic Acid Concentration, Baseline</title>
          <description>Normal Ascorbic Acid Range 0.4-2.0 mg/dL</description>
          <population>Missing Data</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.3" spread="0.3"/>
                    <measurement group_id="B2" value="0.4" spread="0.3"/>
                    <measurement group_id="B3" value="0.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ascorbic Acid Concentrations &lt;0.4 mg/dL, Baseline</title>
          <description>Normal Ascorbic Acid Range 0.4-2.0 mg/dL</description>
          <population>Missing data</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.7"/>
                    <measurement group_id="B2" value="36.6"/>
                    <measurement group_id="B3" value="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PIRO Score, Baseline</title>
          <description>PIRO consists of 4 assessments, Predisposition (scored 0-9), Infection (scored 0-4), Response (scored 0-6), and Organ Failure (scored 0-14). The total PIRO score is the sum of all subscores and ranges from 0-33 with higher scores indicating worse health</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.4" spread="3.9"/>
                    <measurement group_id="B2" value="15.9" spread="4.0"/>
                    <measurement group_id="B3" value="15.7" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modified SOFA Score, Baseline</title>
          <description>Sequential Organ Failure Assessment (SOFA) Score included the degree of dysfunction of six organ systems (Respiratory, Cardiovascular, Liver, Renal, Coagulation, Neurologic. A modification of the SOFA includes the exclusion of the Liver function. Total score is reported, minimum score = 0 maximum score = 20. Higher scores indicate greater degree of dysfunction.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="2.5"/>
                    <measurement group_id="B2" value="5.0" spread="2.3"/>
                    <measurement group_id="B3" value="5.1" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ICU Admission</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Modified SOFA Score</title>
        <description>Sequential Organ Failure Assessment (SOFA) Score included the degree of dysfunction of six organ systems (Respiratory, Cardiovascular, Liver, Renal, Coagulation, Neurologic. A modification of the SOFA includes the exclusion of the Liver function. Total score is reported, minimum score = 0 maximum score = 20. Higher scores indicate greater degree of dysfunction.</description>
        <time_frame>Baseline and 72 hours</time_frame>
        <population>Data was not available for 3 participants in the treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose IV Ascorbic Acid</title>
            <description>Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.&#xD;
Ascorbic Acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Modified SOFA Score</title>
          <description>Sequential Organ Failure Assessment (SOFA) Score included the degree of dysfunction of six organ systems (Respiratory, Cardiovascular, Liver, Renal, Coagulation, Neurologic. A modification of the SOFA includes the exclusion of the Liver function. Total score is reported, minimum score = 0 maximum score = 20. Higher scores indicate greater degree of dysfunction.</description>
          <population>Data was not available for 3 participants in the treatment group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="4.4"/>
                    <measurement group_id="O2" value="-1.75" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.631</p_value>
            <method>Other</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified SOFA Score</title>
        <description>Sequential Organ Failure Assessment (SOFA) Score included the degree of dysfunction of six organ systems (Respiratory, Cardiovascular, Liver, Renal, Coagulation, Neurologic. A modification of the SOFA includes the exclusion of the Liver function. Total score is reported, minimum score = 0 maximum score = 20. Higher scores indicate greater dysfunction.</description>
        <time_frame>at 72 Hours</time_frame>
        <population>Data was not available for 3 participants in the treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose IV Ascorbic Acid</title>
            <description>Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.&#xD;
Ascorbic Acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Modified SOFA Score</title>
          <description>Sequential Organ Failure Assessment (SOFA) Score included the degree of dysfunction of six organ systems (Respiratory, Cardiovascular, Liver, Renal, Coagulation, Neurologic. A modification of the SOFA includes the exclusion of the Liver function. Total score is reported, minimum score = 0 maximum score = 20. Higher scores indicate greater dysfunction.</description>
          <population>Data was not available for 3 participants in the treatment group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="4.8"/>
                    <measurement group_id="O2" value="3.3" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.640</p_value>
            <method>Other</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ascorbic Acid Concentration at 32 Hours</title>
        <description>Ascorbic Acid Concentration Normal Ascorbic Acid Range 0.4-2.0 mg/dL</description>
        <time_frame>32 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose IV Ascorbic Acid</title>
            <description>Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.&#xD;
Ascorbic Acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Ascorbic Acid Concentration at 32 Hours</title>
          <description>Ascorbic Acid Concentration Normal Ascorbic Acid Range 0.4-2.0 mg/dL</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="10.9"/>
                    <measurement group_id="O2" value="0.22" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Length of Stay</title>
        <description>ICU Length of Stay in Hours</description>
        <time_frame>Length of ICU stay up to 200 hours</time_frame>
        <population>Data was not available for 7 participants in both groups.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose IV Ascorbic Acid</title>
            <description>Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.&#xD;
Ascorbic Acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Length of Stay</title>
          <description>ICU Length of Stay in Hours</description>
          <population>Data was not available for 7 participants in both groups.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="6" upper_limit="187"/>
                    <measurement group_id="O2" value="47" lower_limit="39" upper_limit="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.655</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <description>From admission until discharge from ICU in days</description>
        <time_frame>From ICU admission through ICU discharge, up to 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose IV Ascorbic Acid</title>
            <description>Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.&#xD;
Ascorbic Acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <description>From admission until discharge from ICU in days</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="5" upper_limit="9"/>
                    <measurement group_id="O2" value="6" lower_limit="4" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.133</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PIRO Score</title>
        <description>PIRO consists of 4 assessments, Predisposition (scored 0-9), Infection (scored 0-4), Response (scored 0-6), and Organ Failure (scored 0-14) (PIRO). The total PIRO score is the sum of all subscores and ranges from 0-33 with higher scores indicating worse health.</description>
        <time_frame>Baseline and 72 hours</time_frame>
        <population>Data was not available for 3 participants in the treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose IV Ascorbic Acid</title>
            <description>Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.&#xD;
Ascorbic Acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PIRO Score</title>
          <description>PIRO consists of 4 assessments, Predisposition (scored 0-9), Infection (scored 0-4), Response (scored 0-6), and Organ Failure (scored 0-14) (PIRO). The total PIRO score is the sum of all subscores and ranges from 0-33 with higher scores indicating worse health.</description>
          <population>Data was not available for 3 participants in the treatment group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="3"/>
                    <measurement group_id="O2" value="-4.5" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.566</p_value>
            <method>Other</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Died</title>
        <time_frame>From initial hospital admission through discharge, up to 2 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose IV Ascorbic Acid</title>
            <description>Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.&#xD;
Ascorbic Acid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.&#xD;
Normal Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Died</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High Dose IV Ascorbic Acid</title>
          <description>Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.&#xD;
Ascorbic Acid</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.&#xD;
Normal Saline</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <description>Short of breath during the 48-72 hour post randomization.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia (HR increase 20 bpm)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension (SBP&lt; 90)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jamie Rosini, Pharm D</name_or_title>
      <organization>Christiana Care Health Services</organization>
      <phone>302-733-6364</phone>
      <email>jrosini@christianacare.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

